The story of the tumor detection market needs to be told again.

Since 2000, Illumina has become a sequencing giant through key technology acquisitions, laying the foundation for the survival of the entire industry. But Wall Street's interest has gradually shifted towards new players, such as Natera.

Natera holds a near monopoly position in the market for minimal residual disease (MRD) detection. In the past two to three years, the stock price of this company has more than quadrupled, with a market value approaching $50 billion. Compared to that, Illumina's market value hovers around $30 billion. Investors believe that behind Natera is a new era of blood cancer testing.

Of course, Natera is not the only notable 'shovel seller'. As mRNA tumor vaccines are about to be commercialized, many upstream companies are being repriced.

In August, during the trading week when Moderna and Merck announced the success of Phase III clinical trials for mRNA tumor vaccines, Tempus AI's stock price surged by about 40%, and in just two trading days, its market value increased by more than $3 billion - almost twice the trading price of its acquisition of Personalizs ($1.5 billion). And Personalis' stock price broke through Tempus' acquisition price of $16.25 and soared to $18 at one point.

For a transaction that has already signed an agreement, this phenomenon is quite rare. The trend of the Wall Street market indicates that those who truly make money may be the "shovel sellers", and Tempus is that shovel, or more accurately, it is striving to become the "golden shovel".

01. Premium acquisition

On July 20th, Tempus announced the acquisition of all outstanding shares of Personalis for $16.25 per share, with a trading value of approximately $1.5 billion.

This price represents a premium of approximately 6% compared to the closing price of Personalis on the previous trading day, and a premium of 28% compared to the volume weighted average price unaffected on the 30th. From a financial perspective, it can be considered a respectable acquisition. But the first reaction of the market was not applause.

On the day of the announcement, Tempus' stock price fell 4.71% in pre-market trading, and Personalis also fell 4.57%.

Considering that Tempus already holds nearly 12.5% of Personalis' shares, investors question whether this transaction is a strategic integration or a disguised "buy and sell"? Moreover, Personalis' stock price fell to $16.39 during trading that day, almost at the acquisition price.

A month later, the narrative underwent a reversal.

On the second day after Moderna and Merck released their Phase III data on Intismeran Autogene, Tempus' stock price surged 24.1% in a single day and another 8.8% the next day, with a cumulative increase of 39.5% over two trading days.

BTIG analyst Mark Massaro quickly raised Tempus' target price from $70 to $80, maintaining a 'buy' rating. His reason is that if this vaccine is approved for market, each patient will need to have their tumor tissue sequenced before receiving treatment. The NeXT Platform developed by Personalizs is a crucial step in this process, and Tempus is about to take it into its own hands.

Personalizs is not a big company yet. According to its Q2 2026 financial report, its clinical revenue was only $2.6 million, which is a year-on-year increase of 442%. But now, it has become a name that the entire Wall Street is eagerly discussing.

The market has new expectations that this transaction may be marked up. The stock price of Personalizs broke through the acquisition price of $16.25 after the vaccine data was released, reaching $18. Under normal circumstances, the stock price of the acquired party will trade at a slightly lower level than the acquisition price to reflect the risk of the transaction potentially breaking down.

Premium means that someone is betting on a more favorable offer or bidding war.

The transaction agency documents subsequently released by Tempus confirmed this speculation - before agreeing to Tempus' offer, Personalis had contacted multiple potential buyers, including a verbal offer of $17 per share. Wall Street analysts speculate that diagnostic companies such as Natera and Guardant Health may be potential bidders.

Currently, Tempus holds approximately 12% of Personalis shares, and Merck has agreed to vote in favor of this transaction with its approximately 13% stake. By calculation, about a quarter of the voting rights have already taken sides.

But whether other shareholders will push for higher prices is still unknown. Several shareholder equity law firms have announced investigations into the acquisition, with a focus on whether the transaction price is fair and whether the board of directors has fulfilled its fiduciary obligations.

As of early September, this transaction is expected to be completed by the end of 2026 or early 2027, pending approval from shareholders and regulatory authorities. But the market is already voting with real money: Tempus' market value once reached about $11.69 billion, with a trading valuation of about 7.5 times its 2026 revenue guidance median of $1.6 billion.

02. Second gambling game

Tempus' obsession with Personalis can be traced back to a key figure, Eric Lefkofsky。

Lefkofsky is a co-founder of Groupon. Groupon was valued at over $12 billion when it went public in 2011, but quickly collapsed and its market value evaporated shortly after its IPO. Lefkofsky himself cashed out over $300 million from the IPO, leaving some unpleasant memories on Wall Street.

In 2015, Lefkofsky founded Tempus Labs, initially positioned as an "AI driven precision medicine company". On the eve of its IPO in 2024, the company was renamed Tempus AI, probably hoping to be valued as a technology company rather than a diagnostic laboratory.

Unfortunately, the capital market did not buy it at that time. Tempus has always been one of the most heavily shorted stocks in the healthcare sector, with a valuation of only about 6 times expected sales, while its faster growing peers such as Guardant Health, Grail, and Natera are around 13 times.

The problem is not that Tempus has no business. On the contrary, its business has grown rapidly.

In the second quarter of 2026, Tempus' total revenue reached $382.5 million, a year-on-year increase of 22%, of which the diagnostic business contributed $289.3 million and the tumor detection volume increased by 31% year-on-year.

More importantly, Tempus recorded its first GAAP net profit since going public in this quarter, reaching $5.6 million, although it included approximately $55.6 million in equity incentive expenses and $98.5 million in unrealized securities gains.

Tempus expects its annual revenue for 2026 to be between $1.595 billion and $1.605 billion, with an adjusted EBITDA of approximately $65 million. As of June 30th, the cash and sellable securities on hand amounted to $820.7 million - enough to support Personalis trading, but not without pressure.

The core reason why Personality excites Lefkofsky is the detection of minimal residual lesions, also known as MRD.

The logic of MRD is not complicated. After surgery, are there still cancer cells in the blood of cancer patients that cannot be detected by naked eye or imaging? If these trace amounts of circulating tumor DNA can be detected before recurrence is detected by traditional imaging scans, doctors can intervene earlier, and chemotherapy is much more effective in clearing trace lesions than in clearing visible tumors.

NeXT Personal from Personalis is a "tumor informed" MRD test: the patient's excised tumor tissue is first sequenced to identify its unique gene mutations, and then a personalized blood test is constructed to track these mutations in subsequent blood samples.

This process naturally overlaps with the sequencing requirements of mRNA cancer vaccines - the same tumor sequence can be used for both vaccine design and postoperative monitoring.

Bioaxia CEO Douglas Eby holds shares in both Tempus and Personalizs, and he believes that once the mRNA tumor vaccine business takes off, Tempus will have a strong entry point into the MRD market. The initial sequencing of vaccines brings patients into the Tempus ecosystem, while recurrent MRD monitoring may keep patients in this ecosystem for years or even longer.

Piper Sandler estimates that if the vaccine is approved for melanoma, sequencing revenue alone would be at least $50 million annually. When the indications expand to lung cancer, bladder cancer and kidney cancer, BTIG analyst Mark Massaro estimates that this number may exceed 600 million dollars. If MRD business also takes off, the opportunities will be much greater.

This is Lefkofsky's second gamble, using a story of "selling shovels" to get rid of the valuation shadow left by Groupon.

03. Game of Thrones

Tempus is not the first company to see MRD opportunities. In fact, it entered a market that already had a clear dominant player.

Natera, also located in the United States, is almost a monopolistic presence in the MRD field. Its flagship product Signatera adopts the same "tumor informed" logic as Personalis NeXT Personal: sequencing tumor tissue first, and then customizing blood testing.

In the first quarter of 2026, Signatera's clinical testing volume reached approximately 283000 cases, a year-on-year increase of approximately 56%, and the average realized value per case increased to approximately $1275. As a result, Natera's revenue has grown from approximately $1 billion in 2023 to $2.3 billion in 2025- analysts predict it will reach $2.77 billion by 2026.

As of September 11th, Natera's market value has exceeded $47 billion, surpassing Illumina, which is essential for the survival of the entire sequencing industry.

But Natera's dominant position also brought its own problems. Trading at a valuation of 10 to 11 times future revenue means that any imperfect growth will trigger a sell-off. In May 2026, Natera announced a 39% year-on-year increase in revenue for the first quarter, reaching $697 million, but the stock price still fell by about 10%.

Natera's moat is not insurmountable. Guardant Health is the closest competitor, and its Reveal detection uses a "tissue free" route, which does not require sequencing of tumor tissue first, but directly searches for ctDNA from the blood.

This route is more convenient in operation, but usually not as sensitive as the tumor informed protocol. Guardant's oncology business achieved a 26% annual revenue growth and a 34% increase in testing volume by 2025, mainly driven by the rapid adoption of Guardant360 and Reveal.

Although Tempus and Personalizs are "small players" in this landscape, they have something that Natera does not possess - a deep binding with the mRNA tumor vaccine project.

Personalis is a tumor sequencing partner in the Moderna clinical project, while Tempus has been designated as the sequencing partner after vaccine approval. If Intiseman Autogene goes commercial, Tempus may get a ticket at the starting point.

The only concern is that this logical chain has a fragile premise: vaccines must be approved and sold.

Leerink Partners analyst Puneet Souda estimates that the current market penetration rate for MRD testing is only about 6%, corresponding to a $20 billion US market. Low penetration rate represents a large growth potential, but it also means that the education market and the promotion of clinical guideline adoption require time.

Medicare has already paid for MRD testing, but commercial insurance covering approximately half of the eligible population only has a payment rate of about 25%. TD Cowen analyst Dan Brennan pointed out that the real catalyst will come from clinical trials of larger cancer types that produce positive results and drive recommendations from guideline agencies such as NCCN.

Natera has submitted advanced test data in the FDA application for bladder cancer, which shows that the survival period of patients with positive detection has improved after receiving intervention. Bladder cancer is a small market, and its major focus is colorectal cancer, lung cancer and other major diseases.

In addition, Japan is a more powerful catalyst. In June, Signatera's application for colorectal cancer was approved by the Japanese regulatory authorities. Unlike the fragmented payment system in the United States, Japan's single national insurance system may open up nationwide access for Signatera.

Tempus entered this market in a different way than Natera.

It does not intend to compete head-on with Natera from scratch, but attempts to use the mRNA vaccine as a "wedge" to pry open an entrance. Vaccines require sequencing, sequencing requires diagnostic partners, and diagnostic partners can extend to MRD monitoring.

04. Are boots on the ground?

The success of Moderna and Merck is certainly inspiring, but to what extent this result represents a victory for the industry remains to be seen.

In August, another pair of mRNA tumor vaccine partners - BioNTech and Genentech - announced the termination of the phase II clinical trial of autogene cevumeran in colorectal cancer due to a "numerical imbalance" between the overall survival of the vaccine treatment group and the control group.

BioNTech emphasized that no new safety signals were found, which still poured cold water on the entire field.

Some differences are worth examining in detail. The terminated trial tested the efficacy of autogene cevumeran as monotherapy, while in the trials of Moderna and Merck, intismeran was used in combination with Keytruda.

More importantly, there are differences in cancer types. Melanoma belongs to the category of "heat tumors" and has a high burden of tumor mutations, making it naturally more suitable for immunotherapy. Colorectal cancer is usually considered a "cold tumor" with less expression of new antigens, making it more difficult for the immune system to recognize and attack.

In addition, even if positive results are obtained in 'hot tumors', there are still significant obstacles on the commercialization path, such as costs.

William Blair, an analyst, assumes that Intismeran's wholesale purchase price in the United States is $475000 per patient, based on the pricing level of approved tumor cell therapy products. According to the Phase III plan, the total price of using Keytruda in combination will be close to 700000 US dollars.

But the real cost pressure still lies in manufacturing. The production logic of intesmeran is completely different from that of traditional vaccines - millions of doses of traditional vaccines can be produced at one time, and the fixed cost can be massively diluted; Personalized cancer vaccines are "one person, one medicine", with each patient being an independent batch.

According to reports, Moderna's turnaround time from sample collection to medication has been shortened to about 6 weeks, and its dedicated factory has started supplying clinical batches in September 2025 and is preparing for potential commercialization.

There is also a historic warning here, Provenge。 When the product was approved in 2010, Dendreon had ambitions to turn it into a heavyweight bomb, but it was a real mess. The manufacturing cost of Provenge was initially close to 77% of its selling price, with a market price of $93000. Dendreon filed for bankruptcy in less than five years.

The limitations of the indications for mRNA tumor vaccines also need to be taken seriously. At present, the positive data for intismeran is only for adjuvant therapy after melanoma surgery. The expansion to lung cancer, bladder cancer and kidney cancer is inseparable from new trials, and each research needs time and money.
The failure of BioNTech in colorectal cancer reminds people that "cold tumors" may not be as easily conquered as "hot tumors".

For Tempus and Personalis, these uncertainties pose a potentially fatal challenge: their 'shovel selling' stories are built on the premise of successful vaccine commercialization, but this is far from a definite event.

If Intiseman is ultimately approved only for the small indication of melanoma, Piper Sandler's estimated $50 million in annual sequencing revenue, although considerable, is far from enough to support Tempus' current market expectation based on a valuation of 7.5 times revenue.

A more subtle risk is that pharmaceutical companies may choose to internalize the sequencing process.

Moderna and Merck rely on external partners for tumor sequencing, and as personalized vaccines become a core business, the temptation to incorporate this into their own value chain will become even greater. Moderna has established a dedicated factory, who can guarantee that it will not build its own sequencing capabilities in the future?
Walker hopes that data can open up new possibilities - the "data wealth" accumulated from tens of thousands of unique tumor biopsies may ultimately help identify shared targets and develop "spot type" cancer vaccines, transforming from "one person, one test" to "one sequencing, serving multiple people".

However, until that day arrives, Tempus' gamble is still a game of probability.

This company is betting that mRNA cancer vaccines will truly enter a golden age, sequencing demand will continue to grow, MRD monitoring will become standard care, and it will find a sufficiently large position in the pincer of Natera and Guardant.

Reference materials: 

1 The Cancer Vaccine Gold Rush Has Begun. So Has the Race for Picks and Shovels.
2 The Cancer Test That Wall Street Is Betting On
3 mRNA cancer vaccines’ biggest barriers to market
4. Is a cancer vaccine worth nearly $500000 per dose? When mRNA begins to settle accounts; Same freehand brushwork